Cargando…

Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is a chronic autoimmune disease with relapse–remission courses. A number of patients may present with a refractory disease with partial or no response to treatment. Others may present with extra-intestinal manifestations that makes the treatment with one biologic cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdullah, Israa, AlMojil, Khaled, Shehab, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680431/
https://www.ncbi.nlm.nih.gov/pubmed/36412596
http://dx.doi.org/10.3390/diseases10040102
_version_ 1784834416170762240
author Abdullah, Israa
AlMojil, Khaled
Shehab, Mohammad
author_facet Abdullah, Israa
AlMojil, Khaled
Shehab, Mohammad
author_sort Abdullah, Israa
collection PubMed
description Inflammatory bowel disease (IBD) is a chronic autoimmune disease with relapse–remission courses. A number of patients may present with a refractory disease with partial or no response to treatment. Others may present with extra-intestinal manifestations that makes the treatment with one biologic challenging. Dual target therapy (DTT), combining biologics and/or small molecule drugs, may offer a chance to achieve remission in these cases and improve patients’ quality of life despite the limited evidence regarding this approach. We present a case series of refractory inflammatory bowel disease cases managed with DTT. Seven patients with refractory IBD achieved steroid free, clinical, and endoscopic remission by using DTT. These results support that DTT could be an effective approach in selected patients with refractory IBD or with concomitant extra-intestinal manifestations (EIM). Larger studies, ideally randomized controlled trials, are needed to further support the evidence and confirm the efficacy and safety of DTT for IBD.
format Online
Article
Text
id pubmed-9680431
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96804312022-11-23 Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease Abdullah, Israa AlMojil, Khaled Shehab, Mohammad Diseases Article Inflammatory bowel disease (IBD) is a chronic autoimmune disease with relapse–remission courses. A number of patients may present with a refractory disease with partial or no response to treatment. Others may present with extra-intestinal manifestations that makes the treatment with one biologic challenging. Dual target therapy (DTT), combining biologics and/or small molecule drugs, may offer a chance to achieve remission in these cases and improve patients’ quality of life despite the limited evidence regarding this approach. We present a case series of refractory inflammatory bowel disease cases managed with DTT. Seven patients with refractory IBD achieved steroid free, clinical, and endoscopic remission by using DTT. These results support that DTT could be an effective approach in selected patients with refractory IBD or with concomitant extra-intestinal manifestations (EIM). Larger studies, ideally randomized controlled trials, are needed to further support the evidence and confirm the efficacy and safety of DTT for IBD. MDPI 2022-11-09 /pmc/articles/PMC9680431/ /pubmed/36412596 http://dx.doi.org/10.3390/diseases10040102 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Abdullah, Israa
AlMojil, Khaled
Shehab, Mohammad
Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease
title Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease
title_full Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease
title_fullStr Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease
title_full_unstemmed Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease
title_short Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease
title_sort effectiveness of dual biologic or small molecule therapy for achieving endoscopic remission in refractory inflammatory bowel disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680431/
https://www.ncbi.nlm.nih.gov/pubmed/36412596
http://dx.doi.org/10.3390/diseases10040102
work_keys_str_mv AT abdullahisraa effectivenessofdualbiologicorsmallmoleculetherapyforachievingendoscopicremissioninrefractoryinflammatoryboweldisease
AT almojilkhaled effectivenessofdualbiologicorsmallmoleculetherapyforachievingendoscopicremissioninrefractoryinflammatoryboweldisease
AT shehabmohammad effectivenessofdualbiologicorsmallmoleculetherapyforachievingendoscopicremissioninrefractoryinflammatoryboweldisease